Astonea Labs Ltd. Board Meeting Approves Variation in IPO Objects, Grants Omnibus Approval for Material Related Party Transactions, and Adopts New AoA

In a recent board meeting, Astonea Labs Ltd. approved a variation in the objects of their Initial Public Offer (IPO), granting omnibus approval for material related party transactions for the financial year 2026-27, and adopting a new set of Articles of Association (AoA). The IPO variation includes utilizing a portion of the unutilized IPO proceeds of Rs. 6,25,00,000 towards the acquisition of equity shares of Damaira Pharmaceuticals Private Limited, resulting in a Company stake of approximately 20-21%. The omnibus approval for related party transactions covers transactions proposed to be entered into with identified related parties during FY 2026-27, amounting to Rs. 415.00 Crores. The new AoA aims to align the Company’s Articles of Association with the latest regulatory requirements and ensure compliance with applicable laws and SEBI regulations.